Pisani P, Krengli M
G Ital Oncol. 1989 Apr-Sep;9(2-3):87-91.
Our study analyze retrospectively 102 patients (96 male and 6 female), affected by laryngeal carcinoma with histological lymph node metastases, who came under observation from 1978 to 1984. All patients underwent partial (25 cases) or total (77 cases) laryngectomy with functional neck dissection and postoperative radiotherapy with functional neck dissection and postoperative radiotherapy. Irradiation to the neck was administered, employing Cobalt 60, through two lateral opposing fields or an anterior and two posterior fields for a total dose of 50-60 Gy (fraction of 2 Gy for 5 days/week). According to UICC classification (1982) the distribution of cases was as follow: 4 T1, 28 T2, 54 T3, 16 T4. Relatively to the localization of the tumours we had 63 supraglottic, 35 glottic and 4 subglottic involvement. The histological grading was certified in 68 cases: 12 G1, 39 G2, 17 G3; extracapsular spread was found in 20/54 cases (37%). The actuarial global and NED survivals of the whole study were respectively 68.5% and 59.8% for 3 years and 56.5% and 48.2% for 5 years. In relation to the T the global and NED survival for 5 years 67.7% and 61.8% for T1-T2 and 53.1% and 46.4% for T3. The recurrences, observed in 26 patients were found, after 3 years follow up, in 25% of G1, 20.5% of G2 and 47.1% of G3. With relation to the integrity of the nodal capsule N-recurrences were found in 20% of R+ and 5.9% of R-. At the end of the Authors underline the importance of postoperative radiotherapy in the treatment of histological N+ cancers of the larynx and the significance of histological grading and extra-capsular spread in cervical nodes as prognostic factors.
我们的研究回顾性分析了1978年至1984年间接受观察的102例喉癌伴组织学淋巴结转移患者(96例男性,6例女性)。所有患者均接受了部分喉切除术(25例)或全喉切除术(77例),并进行了功能性颈清扫术及术后放疗。颈部放疗采用钴60,通过两个相对的侧野或一个前野和两个后野进行,总剂量为50 - 60 Gy(每周5天,每次2 Gy)。根据UICC分类(1982年),病例分布如下:4例T1,28例T2,54例T3,16例T4。关于肿瘤的部位,声门上区受累63例,声门区35例,声门下区4例。68例患者有组织学分级:12例G1,39例G2,17例G3;54例中有20例(37%)发现有包膜外扩散。整个研究的精算总生存率和无病生存率3年分别为68.5%和59.8%,5年分别为56.5%和48.2%。就T分期而言,T1 - T2期5年总生存率和无病生存率分别为67.7%和61.8%,T3期为53.1%和46.4%。26例患者出现复发,在3年随访后,G1级患者复发率为25%,G2级为20.5%,G3级为47.1%。关于淋巴结包膜的完整性,R +患者N复发率为20%,R -患者为5.9%。作者最后强调了术后放疗在治疗喉组织学N +癌症中的重要性,以及组织学分级和颈部淋巴结包膜外扩散作为预后因素的意义。